Tirzepatide…
Do Weight Loss Differently
The US Food and Drug Administration (FDA) approved the use of Tirzepatide for treating type 2 diabetes mellitus (T2DM). Tirzepatide is a synthetic polypeptide and dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Therefore, the drug leads to significantly improved glycemic control and weight reduction in patients with T2DM, maximizing benefits similar to GLP-1 medications such as Semaglutide.
Medical Uses
Tirzepatide is an injectable prescription medicine that helps your body regulate blood sugar and helps decrease how much food you eat in adults with type 2 diabetes. Tirzepatide is not for use in people with type 1 diabetes.
In studies with or without diabetes medications, 75% to 90% of people taking Tirzepatide reached an A1C of less than 7%, with an average starting A1C of 7.9% to 8.6% across the 5-mg, 10-mg, and 15-mg doses.
Study results were measured at 40 and 52 weeks.
In studies with or without diabetes medications, 75% to 90% of people taking Tirzepatide reached an A1C of less than 7%, with an average starting A1C of 7.9% to 8.6% across the 5-mg, 10-mg, and 15-mg doses.
Study results were measured at 40 and 52 weeks.
Tirzepatide Works in Multiple Ways
Tirzepatide functions as both a GIP and GLP-1 receptor agonist. By targeting these receptors, Tirzepatide helps regulate blood sugar levels, suppress appetite by slowing digestion, and promote weight loss. An agonist is a substance that binds to a specific receptor, triggering a physiological response. (Roll over image on right to see how Tirzepatide works with the body)
Just Published in the New England Journal
“As part of a weight loss program, the use of semaglutide helped people with weight gain lose an average of 15% of their body weight during 68 weeks of treatment. This equated to an average of 34 pounds of weight loss during the trial”.
Other Uses
People taking Tirzepatide lost up to 25lbs. Individual results may vary. In studies with or without other diabetes medications, weight loss in adults ranged from 12 lb (5 mg) to 25 lb (15 mg).
Mechanism of Action
Tirzepatide is a synthetic polypeptide dual agonist for GLP-1 and GIP. Tirzepatide, “twincretin,” exhibits distinct characteristics from GLP-1 receptor agonists. The medication comprises 39 amino acids and is an analog of the gastric inhibitory polypeptide. Functionally, Tirzepatide stimulates insulin release from the pancreas and reduces hyperglycemia. In addition, Tirzepatide also increases the levels of adiponectin.
The dual agonism ability decreases hyperglycemia significantly more than GLP-1 agonist agents and reduces the patient’s appetite. Among patients without diabetes, administering Tirzepatide 5 to 15 mg once weekly for managing obesity led to remarkable reductions in body weight, ranging from 16.5% to 22.4% over 72 weeks. Post hoc analyses of fasting biomarkers indicated that Tirzepatide exhibited more significant improvements in markers of insulin sensitivity and β-cell function.
Achieve up to 30% weight loss
30%
Reach an A1C under 7% or lower
7%
